Tandem Diabetes Care Stock Analysis

TNDM Stock  USD 31.86  1.64  4.90%   
Tandem Diabetes Care is undervalued with Real Value of 34.02 and Target Price of 39.33. The main objective of Tandem Diabetes stock analysis is to determine its intrinsic value, which is an estimate of what Tandem Diabetes Care is worth, separate from its market price. There are two main types of Tandem Diabetes' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Tandem Diabetes' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Tandem Diabetes' stock to identify patterns and trends that may indicate its future price movements.
The Tandem Diabetes stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tandem Diabetes is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Tandem Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Tandem Diabetes' ongoing operational relationships across important fundamental and technical indicators.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Tandem Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 494.25. Tandem Diabetes Care recorded a loss per share of 3.43. The entity last dividend was issued on the 10th of October 2017. The firm had 1:10 split on the 10th of October 2017. Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about Tandem Diabetes Care contact Kim Blickenstaff at 858 366 6900 or learn more at https://www.tandemdiabetes.com.

Tandem Diabetes Care Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Tandem Diabetes' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Tandem Diabetes Care or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Tandem Diabetes Care appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 412.99 M.
Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47.
Tandem Diabetes Care has a frail financial position based on the latest SEC disclosures
Over 99.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: DexCom , MD Revolution Unite to Boost Diabetes Management

Tandem Diabetes Care Upcoming and Recent Events

Earnings reports are used by Tandem Diabetes to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tandem Diabetes previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Tandem Largest EPS Surprises

Earnings surprises can significantly impact Tandem Diabetes' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-03
2021-09-300.060.090.0350 
2023-11-01
2023-09-30-0.34-0.38-0.0411 
2022-02-22
2021-12-310.210.16-0.0523 
View All Earnings Estimates

Tandem Diabetes Thematic Classifications

In addition to having Tandem Diabetes stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Drugs Idea
Drugs
Drug manufacturing and delivery

Tandem Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tandem Diabetes is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tandem Diabetes Care backward and forwards among themselves. Tandem Diabetes' institutional investor refers to the entity that pools money to purchase Tandem Diabetes' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Gw&k Investment Management, Llc2023-12-31
1.2 M
Capital Research & Mgmt Co - Division 32023-12-31
1.1 M
Paradice Investment Management Llc2023-12-31
1.1 M
Voloridge Investment Management, Llc2023-09-30
M
Geode Capital Management, Llc2023-12-31
M
Two Sigma Advisers, Llc2023-12-31
M
Stephens Inv Mgmt Group Llc2023-12-31
962.3 K
Morgan Stanley - Brokerage Accounts2023-12-31
872.2 K
Jacobs Levy Equity Management, Inc.2023-09-30
793.5 K
Blackrock Inc2023-12-31
9.2 M
Vanguard Group Inc2023-12-31
M
Note, although Tandem Diabetes' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tandem Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tandem Diabetes's market, we take the total number of its shares issued and multiply it by Tandem Diabetes's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Tandem Profitablity

Tandem Diabetes' profitability indicators refer to fundamental financial ratios that showcase Tandem Diabetes' ability to generate income relative to its revenue or operating costs. If, let's say, Tandem Diabetes is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Tandem Diabetes' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Tandem Diabetes' profitability requires more research than a typical breakdown of Tandem Diabetes' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.18.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.23)(0.25)
Return On Capital Employed(0.31)(0.29)
Return On Assets(0.23)(0.25)
Return On Equity(0.71)(0.67)

Management Efficiency

Tandem Diabetes Care has return on total asset (ROA) of (0.0963) % which means that it has lost $0.0963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.29. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 16th of April 2024, Net Tangible Assets is likely to grow to about 531.2 M, while Intangibles To Total Assets are likely to drop 0.
Last ReportedProjected for Next Year
Book Value Per Share 4.83  4.59 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 4.78  4.55 
Enterprise Value Over EBITDA(19.27)(20.24)
Price Book Value Ratio 6.13  4.71 
Enterprise Value Multiple(19.27)(20.24)
Price Fair Value 6.13  4.71 
Enterprise Value2.1 B2.2 B
The analysis of Tandem Diabetes' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Tandem Diabetes' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Tandem Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.131

Technical Drivers

As of the 16th of April 2024, Tandem Diabetes has the Coefficient Of Variation of 1350.37, risk adjusted performance of 0.0552, and Semi Deviation of 3.49. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tandem Diabetes Care, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Tandem Diabetes Care, which can be compared to its competition. Please validate Tandem Diabetes Care variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Tandem Diabetes is priced more or less accurately, providing market reflects its prevalent price of 31.86 per share. Given that Tandem Diabetes Care has jensen alpha of 0.2235, we advise you to double-check Tandem Diabetes Care's current market performance to make sure the company can sustain itself at a future point.

Tandem Diabetes Care Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tandem Diabetes middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tandem Diabetes Care. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Tandem Diabetes Care Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tandem Diabetes insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Tandem Diabetes Predictive Daily Indicators

Tandem Diabetes intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tandem Diabetes stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tandem Diabetes Corporate Filings

9th of April 2024
Other Reports
ViewVerify
8K
1st of April 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
19th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
11th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
29th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
21st of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
20th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of February 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify

Tandem Diabetes Forecast Models

Tandem Diabetes' time-series forecasting models are one of many Tandem Diabetes' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tandem Diabetes' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Tandem Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tandem Diabetes prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tandem shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tandem Diabetes. By using and applying Tandem Stock analysis, traders can create a robust methodology for identifying Tandem entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.29)(0.31)
Operating Profit Margin(0.31)(0.33)
Net Loss(0.30)(0.31)
Gross Profit Margin 0.49  0.27 

Current Tandem Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tandem analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tandem analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
39.33Buy16Odds
Tandem Diabetes Care current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Tandem analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tandem stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tandem Diabetes Care, talking to its executives and customers, or listening to Tandem conference calls.
Tandem Analyst Advice Details

Tandem Stock Analysis Indicators

Tandem Diabetes Care stock analysis indicators help investors evaluate how Tandem Diabetes stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tandem Diabetes shares will generate the highest return on investment. By understating and applying Tandem Diabetes stock analysis, traders can identify Tandem Diabetes position entry and exit signals to maximize returns.
Begin Period Cash Flow172.5 M
Total Stockholder Equity313.6 M
Capital Lease Obligations130.6 M
Property Plant And Equipment Net164.3 M
Cash And Short Term Investments467.9 M
Cash58.9 M
50 Day M A28.8607
Net Interest Income13 M
Total Current Liabilities195.3 M
Forward Price Earnings1111.1111
Investments-85.7 M
Interest Expense7.6 M
Stock Based Compensation88.1 M
Long Term Debt285 M
Common Stock Shares Outstanding65 M
Tax Provision2.4 M
Quarterly Earnings Growth Y O Y-0.37
Other Current Assets16.6 M
Accounts Payable49.6 M
Net Debt356.8 M
Other Operating Expenses902.2 M
Non Current Assets Total204.7 M
Liabilities And Stockholders Equity952.7 M
Non Currrent Assets Other37.6 M
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.43)
Revenue Per Share
11.509
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.